What is ENOV's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 1.02B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for ENOV?

P/E (TTM) is n/a and 52-week range is $16.70 to $34.28 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s ENOV figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for ENOV?

The company profile lists revenue (TTM) near $2.29B, net income (TTM) near $-110.09B, EPS (TTM) near $-19.27 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Enovis Corp based, and what identifiers does Chartloom list?

The company context section lists headquarters in Wilmington, Delaware, US, 57.6M shares outstanding, ISIN US1940145022 when available from company profile and filing metadata.

Enovis Corp

$ENOV

Health Care · Health Care Equipment & Supplies

IR Run Scenarios

$17.69

+1.49%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

Enovis Corp. operates as a medical technology growth company. The company is headquartered in Wilmington, Delaware and currently employs 7,802 full-time employees. The company went IPO on 2008-05-08. The company is focused on developing clinically differentiated solutions by manufacturing and distributing high-quality medical devices with a range of products used for reconstructive surgery, rehabilitation, pain management and physical therapy. The company operates through two segments: Prevention & Recovery and Reconstructive. The Prevention & Recovery segment provides orthopedic and recovery science solutions, including devices, software, and services across the patient care continuum from injury prevention to rehabilitation after surgery, injury, or from degenerative diseases. The Prevention & Recovery products are marketed under several brand names, such as DJO. The Reconstructive segment provides surgical implant solutions, offering a comprehensive suite of reconstructive joint products for the hip, knee, shoulder, elbow, foot, ankle, and finger and surgical productivity tools. The company also operates a Enovis Growth eXcellence business system (EGX).

Employees

7,802

Website

www.enovis.com/

IPO

2008-05-08

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)